Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis

Shanshan Chen, Yu Liang, Zhangying Feng and Mingxia Wang*

Abstract

Background: Although the dual anti-HER2 therapy, namely, pertuzumab plus trastuzumab and docetaxel, has shown promising results in HER2+ breast cancer patients, whether the dose, efficacy and safety of this treatment differs from those of other pertuzumab-based dual anti-HER2 therapies remain controversial. This systematic review evaluates the efficacy and safety of H (trastuzumab or trastuzumab emtansine ± chemotherapy) + P (pertuzumab) compared with those of H in HER2+ breast cancer patients.

Methods: A comprehensive search was performed to identify eligible studies comparing the efficacy and safety of H + P versus H. The pathologic complete response (pCR), median progression-free survival (PFS) and overall survival (OS) were the primary outcomes, and safety was the secondary outcome. A subgroup analysis of pCR according to hormone receptor (HR) status was performed. All analyses were conducted using STATA 11.0.

Results: Twenty-six studies (9872 patients) were identified. In the neoadjuvant setting, H + P significantly improved the pCR [odds ratio (OR) = 1.33; 95% confidence interval (CI), 1.08–1.63; p = 0.006]. In the metastatic setting, H + P significantly improved PFS [hazard ratios (HRs) = 0.75; 95% CI, 0.68–0.84; p < 0.001]. There was a trend towards better OS but that it did not reach statistical significance (HRs = 0.81; 95% CI, 0.64–1.03; p = 0.082). A subgroup analysis revealed that the HER2+/HR- patients who received H + P showed the highest increase in the pCR. Rash, diarrhea, epistaxis, mucosal inflammation, and anemia were significantly more frequently observed with H + P than with H, whereas myalgia was less frequent (OR = 0.91; 95% CI, 0.82–1.01; p = 0.072), and no significant difference in cardiac toxicity was observed between these therapies (OR = 1.26; 95% CI, 0.81–1.95; P = 0.309).

Conclusions: Our study confirms that H + P is superior to H in the (neo)adjuvant treatment of HER2+ breast cancer, and increase the risk of acceptable and tolerable toxicity (rash, diarrhea, epistaxis, mucosal inflammation, and anemia).

Trial registration: A systematic review protocol was registered with PROSPERO (identification number: CRD42018110415).

Keywords: HER2-positive breast cancer, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Dual-targeted therapy, Molecular targeted therapy

* Correspondence: mxia_wang@163.com

Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, 12 Jiankang Road, PO Box 050011, Shijiazhuang, China

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Human epidermal growth factor receptor 2 (HER2) + breast cancer is one of the most common types of breast cancer, and HER2 is amplified or overexpressed in 15 to 20% of all breast cancer patients [1]. It has been demonstrated that HER2+ breast cancer exhibits sensitivity to HER2 inhibitors, such as pertuzumab, trastuzumab, and trastuzumab emtansine. Trastuzumab (Herceptin), a humanized monoclonal antibody, was the first targeted therapy against the HER2 pathway, and its registration trial demonstrated that its combination with chemotherapy significantly improves the overall response rates and survival compared with the effects of chemotherapy alone [2]. Thus, trastuzumab has become the standard treatment for patients with HER2+ breast cancer in all treatment settings. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate consisting of trastuzumab and the cytotoxic agent DM1 (derivative of maytansine), is used for the targeted delivery of cytotoxic molecules to tumors because it potentially increases efficiency and simultaneously reduces toxicity; consequently, T-DM1 has been approved by the US Food and Drug Administration (FDA) in 2013 for the treatment of HER2+ metastatic breast cancer (MBC) patients who showed progression under treatment with trastuzumab and taxane [1, 3, 4].

Although trastuzumab and T-DM1 have shown remarkable benefits in HER2+ breast cancer patients, disease resistance and intolerable toxic reactions to these drugs will invariably develop; thus, novel therapeutic approaches are needed. Significant advances in the development of new treatment combinations can offer a personalized and less aggressive approach for the management of HER2+ breast cancer patients. Pertuzumab, an HER2-targeted monoclonal antibody, inhibits ligand-dependent signaling by preventing HER2/HER3 dimerization and activates antibody-dependent cell-mediated cytotoxicity [5, 6]. Preclinical studies showed that H (trastuzumab or trastuzumab emtansine ± chemotherapy) + P (pertuzumab) is more potent and selective than either monotherapy (H). In contrast to trastuzumab/T-DM1, pertuzumab binds to a separate domain on the extracellular portion of HER2 (domain 2) and by doing so, it prevents formation of homo- and hetero-dimers which are required for activation of HER2 signaling cascade [7]. A study conducted by Cai Z et al. also strongly supports this effect [8].

Over the last decade, increasing evidence from clinical trials regarding the combinatorial use of pertuzumab has become available. The H + P combination could therefore be used to avoid drug resistance because it generates similar results in terms of pathologic complete response (pCR)/progression-free survival (PFS)/overall survival (OS) while reducing toxicity. The results from the CLEOPATRA trial [9] confirmed that the addition of pertuzumab to trastuzumab and docetaxel therapy significantly increases the PFS and OS of patients with HER2 + MBC (median PFS, 19.5 versus 12.4 months; median OS, 56.5 versus 40.8 months). The findings from phase II (NeoSphere) studies substantiate the efficacy and safety of the combination of pertuzumab with HER2-targeted therapy for patients with locally advanced, inflammatory, or early HER2+ breast cancer [10]. Patients administered pertuzumab and trastuzumab plus docetaxel exhibit a significantly improved pCR (45.8%; 95% CI, 36.1–55.7) compared with those administered trastuzumab plus docetaxel (29.0%; 95% CI, 20.6–38.5), and both groups experience a similar number of serious adverse events (AEs). According to phase Ib/Ila trials [11], the addition of pertuzumab to T-DM1 plus docetaxel results in more significant and meaningful clinical improvements in efficacy compared with the effects of T-DM1 plus docetaxel. Additionally, the results from this study showed the safety, maximum tolerated dose, and antitumor activity of the combination of pertuzumab with T-DM1 plus docetaxel in patients with HER2+ locally advanced breast cancer (LABC) or MBC.

In recent years, increasing attention has been paid to dual anti-HER2 therapies with the aim of resolving the occurrence of toxic reactions and the development of resistance. To our knowledge, no systematic analysis of H + P versus H has been reported. The present systematic review aimed to assess the efficacy and safety of H + P versus H in the (neo)adjuvant treatment of operable HER2+ breast cancer as well as metastatic disease and to stratify the other influencing factors.

Methods
Search strategy
The present systematic review and meta-analysis was conducted and reported according to the standards of quality detailed in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The present study was registered at the International Prospective Register of Systematic Reviews (registration number: CRD42018110415).

Studies were identified by searching PubMed, COCHRANE, Science Direct, EMBASE, the clinical trial registry (www.clinicaltrials.gov), and conference proceedings (American Society of Clinical Oncology, European Society of Medical Oncology, San Antonio Breast Cancer Symposium). The reference lists of key trials and review articles comparing H + P with H in the (neo)adjuvant treatment of HER2+ breast cancer were also examined to ensure that no studies were missed.

The databases were searched for studies published between 2005 (based on the first reported trial of pertuzumab efficacy in humans) and December 30, 2018.
Various combinations of text and Medical Subject Headings (MeSH) terms, namely, “Breast Neoplasms OR Cancer OR Carcinomas”, “Pertuzumab OR Perjeta OR Rhumba 2C4”, “Human Epidermal Growth Factor Receptor-2 OR c-erbB-2 OR HER2-Positive”, and the following search string were used in the database searches:“(Breast Neoplasms OR Cancer OR Carcinomas)”AND“(Pertuzumab OR Perjeta OR Rhumba 2C4)”AND“(Human Epidermal Growth Factor Receptor-2 OR c-erbB-2 OR HER2-Positive)”. The following additional filters were included in the database search: “clinical trial”, “full text”, and “species: human”. We considered all potentially qualified studies for review, without restrictions of language or primary outcomes.

Study selection and data extraction
Two reviewers independently screened all the publications first based on their titles and abstracts, and the studies that satisfied the inclusion criteria were then retrieved for full text assessments. Studies were included if they assessed the effectiveness and safety of H + P versus H in patients with HER2+ breast cancer, irrespective of the trial phase, the cohorts (whether prospectively or retrospectively defined), the choice of chemotherapy, and the stage of the HER2+ breast cancer patients, to improve the accuracy of our conclusions. The articles that lacked original data were excluded. If more than one publication reported results from the same trial or included the same or overlapping patient cohorts, only the outcomes from the largest and most recent publication were included.

Two independent reviewers extracted the data from the articles based on a predefined questionnaire. Any discrepancies in study selection or data extraction between reviewers were resolved by consultation with a third reviewer (Mingxia W). The following data were extracted from each study: first author’s name, year of publication, publishing journal, number of enrolled patients, neoplasm staging of patients with HER2+ breast cancer, trial phase, treatment arms, dose of HER2 inhibitors and pertuzumab, choice of chemotherapy, definition of pCR and HR status.

The main endpoints of interest with H + P were pooled to encompass the pCR, PFS, OS, and the incidence of all-grade or grade ≥3 AEs or cardiac toxicity (left ventricular ejection fraction (LVEF) decline < 50% or more than 10% from baseline). pCR was defined as the proportion of patients without invasive cancer in the breast and axilla (ypT0/is and ypN0) since the date of first receiving H + P or H. PFS was defined as the time of first intake of H + P or H until the time of disease progression or death from any cause. OS was defined as the interval from the initial prescription to the first occurrence of death from any cause.

Statistical methods
For controlled trials, the hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled for PFS and OS, and the number of events extracted directly from clinical trials was used to calculate the OR and 95% CI of pCR and adverse reactions. We also extracted pCR, the median PFS (in months), and the proportion of patients with adverse reactions from single-arm trials that applied H + P for the treatment of HER2+ breast cancer. Immature and interim PFS results were not included in the analysis.

The heterogeneity in the results of the studies was evaluated both visually through forest plots and p values and using the I-squared (I²) parameter, which represents the percentage of total variation across studies that is attributable to heterogeneity rather than to chance. P values ≤0.05 were considered significant for heterogeneity, I² < 25% was considered to indicate a low level of heterogeneity and I² > 75% was considered to indicate a high level of heterogeneity. If statistically significant heterogeneity was observed (I² ≥ 50%), a pooled effect was calculated using a random-effect model; otherwise, a fixed-effect model was employed (I² ≤ 50%). A sensitivity analysis was performed by recalculating the pooled outcome estimates after excluding each study one at a time (leave-one-out procedure). The publication bias was evaluated using both Begg’s and Egger’s tests. The quality of the eligible studies was assessed using the Cochrane Handbook for Systematic Reviews of Interventions [12]. All analyses were conducted with STATA 11.0 (State Corporation, Lake Way, Texas, USA). All tests were two-sided, and statistical significance was defined as P < 0.05.

Subgroup analysis
Because the evaluation of biomarkers is highly recommended for the optimal management and decisions of the treatment of breast cancer patients, we divided the patients into two groups according to their HR status (estrogen and/or progesterone receptor positive or negative) to assess the influence of the HR status on the activity of H + P and H. Data on the influence of the HR status on outcomes were lacking in the trials included in the present study; hence, we only analyzed the differences in pCR depending on the HR status.

Results
Characteristics of the included studies
The systematic review process yielded 1469 studies limited to clinical trials from PubMed, COCHRANE, Science Direct, EMBASE, and Clinical Trials.gov, and the screening of the titles and abstracts revealed that 1422 of these articles did not match the eligibility criteria. An additional 21 studies were excluded because they were
duplicates or did not describe outcomes of interest (pCR, PFS, OS, or outcomes of AEs). One additional article was included after a search of the American Society of Clinical Oncology 2016 Annual Meeting abstracts, and two articles were included after an examination of the reference lists of the included studies [9, 13, 14]. Therefore, the remaining 26 reports, which included 9872 HER2+ breast cancer patients, were investigated in the present study [9–11, 13–35]. The PRISMA flow diagram detailing the inclusion and exclusion of publications is shown in Fig. 1. The studies included in our review were published or presented from 2005 to 2018. Of these 26 studies, the 14 single-arm trials with 1098 patients included 13 studies describing pertuzumab combined with trastuzumab for the treatment of HER2+ breast cancer patients [14, 22–33] and one study describing pertuzumab combined with T-DM1 for the treatment of HER2+ breast cancer patients [34], and the 12 controlled trials with 8774 participants (4015 patients and 4759 patients in the experimental and control arms, respectively) included seven studies describing the treatment of patients with pertuzumab combined with trastuzumab versus trastuzumab alone [9, 10, 15–20, 35] and four studies describing the treatment of patients with pertuzumab combined with T-DM1 versus T-DM1 alone [11, 13, 20–22]. Moreover, pCR was reported in four controlled studies and four single-arm studies, the median PFS was reported in five controlled studies and nine single-arm studies, and OS was reported in four controlled studies. The main characteristics of the eligible studies are summarized in Table 1. The results of the quality assessments of the included studies are shown in Table 2.

**Primary outcomes**

**pCR in neoadjuvant studies and subgroup analysis**

Four single-arm trials that included 205 patients were analyzed for the pCR rate in stage -III HER2+ breast cancer patients...
| Study | Phase | Treatment status | HER-2 therapy | Dose | Chemotherapy | Efficacy endpoint | Patients status |
|-------|-------|-----------------|---------------|------|--------------|------------------|----------------|
| Luca Gianni 2018 [22] | 2     | Neoadjuvant | P + T          | 30   | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Palbociclib, Fulvestrant | pCR safety | Unilateral invasive, HER2-positive breast cancer |
| Julia Foldi 2017 [23] | 2     | Neoadjuvant | P + T          | 48   | During weeks 1–12, 840 mg → 420 mg q3w + 4 mg/kg → 2 mg/kg weekly; During weeks 13–24, 420 mg + 6 mg/kg q3w; | Paclitaxel, FEC | pCR safety | stage I–II, HER2-positive invasive breast cancer |
| JASMEET C. SINGH 2017 [24] | retrospective study | Neoadjuvant | P + T          | 57   | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | AC, Paclitaxel | pCR | operable breast cancer (53) locally advanced disease(3) inflammatory breast cancer(1) |
| Shruti R. Tiwari 2016 [25] | retrospective study | Neoadjuvant | P + T          | 70   | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Docetaxel, Carboplatin | pCR safety | HER2-positive MBC/LABC |
| MICHAEL ANDERSSON 2017 [26] | 2     | Metastatic | P + T          | 107  | co-infusion of 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Eribulin | PFS safety | HER2-positive ABC |
| Edith A. Perez 2016 [27] | 2     | Metastatic | P + T          | 106  | Infusion of 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w, respectively | Vinorelbine | PFS safety | HER2-positive MBC/LABC |
| Chau Dang 2015 [28] | 2     | Metastatic | P + T          | 69   | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Docetaxel | PFS safety | HER2-positive MBC |
| Bao D Dao 2015 [29] | retrospective study | Metastatic | P + T          | 19   | NK            | Taxane            | PFS safety | HER2-positive MBC |
| Kazuhiro Araki 2017 [14] | 2     | Metastatic | P + T          | 30   | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Eribulin | PFS safety | HER2-positive ABC |
| Jose’ Baselga 2010 [30] | 2     | Metastatic | P + T          | 66   | 840 mg → 420 mg q3w + 4 mg/kg → 2 mg/kg weekly or 8 mg/kg → 6 mg/kg q3w | NO | PFS safety | HER2-positive MBC |
| Chia C. Portera 2008 [31] | retrospective study | Metastatic | P + T          | 11   | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | NO | safety | HER2-positive MBC |
| Nicholas J. Robert 2017 [32] | retrospective study | Metastatic | P + T          | 266  | NK            | Taxane            | PFS safety | HER2-positive MBC |
| Sabino De Placido 2018 [33] | retrospective study | Metastatic | P + T          | 155  | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Taxane | PFS safety | HER2-positive MBC |
| Kathy D. Miller 2014 [34] | Ib/Iia | Metastatic | P + T-DM1      | 64   | 840 mg → 420 mg q3w + 3.6 mg/kg q3w | NO | safety | HER2-positive MBC/LABC |
| Peter Beitsch 2017 [10] | prospective | Neoadjuvant | A:P + T       | 119  | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Docetaxel, Carboplatin | pCR | T4 or inflammatory HER2-positive breast cancer |
| Luca Gianni 2012 [15] | 2     | Neoadjuvant | A:P + T       | 107  | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Docetaxel | pCR safety | locally advanced, inflammatory, or early-stage HER2-positive breast cancer |
| Gunter von Minckwitz 2017 [16] | prospective | Adjuvant | A:P + T       | 2400 | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | FEC, Docetaxel or Paclitaxel, Carboplatin | safety | HER2-Positive EBC |
| Rashimi K. Murthy 2018 [17] | retrospective study | Neoadjuvant | A:P + T       | 170  | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | Paclitaxel | pCR | Stage II-III HER2-positive Breast Cancer |
| M. Martin 2016 [13] | Ib/Iia | Metastatic | A:P + T-DM1   | 33   | 840 mg → 420 mg q3w + 3.6 mg/kg q3w | Docetaxel | pCR safety | HER2-positive MBC/LABC |
| Mothaffar 2017 | 2     | Metastatic | A:P + T       | 129  | 840 mg → 420 mg q3w + 8 mg/kg → 6 mg/kg q3w | AI | PFS | HER2-positive MBC/LABC |
found among the included individual studies (I² = 0.0%; 
vealed that the HR status contributes to the difference in 
The analysis of pCR outcomes stratified by HR status re-
were estimated to equal 55 and 44%, respectively.

1.08 higher than that of the H group (OR = 1.33; 95% CI, 
that the pCR rate of the H + P group was significantly 
pooled results using a fixed-effects model demonstrated 
occurred in three studies, the results of the benefit ratio 
showed that there was a trend towards better pCR of 
the results of the sensitivity analysis yielded an es-
to chemotherapy, ABC Advanced Breast Cancer, MBC Metastatic Breast Cancer, LABC Locally Advanced Breast Cancer, EBC Early Breast Cancer, HER2 Human Epidermal Growth Factor Receptor 2

### Table 1 Characteristics of the included studies (Continued)

| Study | Phase | Treatment status | HER-2 therapy | Pts. no. | Dosage | Chemotherapy | Efficacy endpoint | Patients status |
|-------|-------|------------------|---------------|----------|--------|--------------|------------------|----------------|
| Rimawi 2017 [18] | Metastatic | A-P + T | 420 mg q3w + 8 mg/kg q3w | 72 | Carboplatin | PFS | HER2-positive MBC |
| Ander Urtucuorea et al. 2017 [9] | Metastatic | A-P + T | 420 mg q3w + 8 mg/kg q3w | 72 | Docetaxel | PFS | HER2-positive MBC |
| Sandra M. Swain et al. 2015 [19] | Metastatic | A-P + T | 420 mg q3w + 8 mg/kg q3w | 72 | Paclitaxel | PFS | HER2-positive MBC/LABC |
| Ian E. Krop et al. 2016 [20] | Metastatic | A-P + T | 420 mg q3w + 3.6 mg/kg q3w or 2.4 mg/kg weekly | 367 | NO | PFS | HER2-positive MBC/LABC |
| Edith A. Perez et al. 2017 [21] | Metastatic | A-P + T | 420 mg q3w + 3.6 mg/kg q3w | 367 | NO | PFS | HER2-positive MBC/LABC |
| Manish Gupta 2013 [11] | Metastatic | A-P + T | 420 mg q3w + 3.6 mg/kg q3w | 367 | NO | PFS | HER2-positive MBC/LABC |
| Nadia Hussain et al. 2018 [35] | Retrospective study | A-P + T | 420 mg q3w + 3.6 mg/kg q3w | 367 | NO | PFS | HER2-positive MBC/LABC |

Abbreviations: T Trastuzumab, P Pertuzumab, T-DM1 Trastuzumab emtansine, AC Doxorubicin, Cyclophosphamide, FEC Fluorouracil (5FU), Epirubicin, and Cyclophosphamide, AI Aromatase Inhibitor, pts patients number, mg milligram, kg kilogram, q3w three-weekly, NK unknown, NO without chemotherapy, ABC Advanced Breast Cancer, MBC Metastatic Breast Cancer, LABC Locally Advanced Breast Cancer, EBC Early Breast Cancer, HER2 Human Epidermal Growth Factor Receptor 2

*a* randomized controlled trials

cancer patients treated with neoadjuvant H + P [10, 13, 
15, 17]. The pCR rates ranged from 0.27 to 0.62 in the four studies, and the pooled results using a random ef-

Four controlled trials including 1448 patients (n = 383 in the experimental H + P groups and n = 1065 in the control H groups) were analyzed for the pCR rate in stage -III HER2+ breast cancer patients [22–25]. The pooled results using a fixed-effects model demonstrated that the pCR rate of the H + P group was significantly higher than that of the H group (OR = 1.33; 95% CI, 1.08–1.63; P = 0.006) (Fig. 2b). Low heterogeneity was found among the included individual studies (I² = 2.07%; P = 0.126). More-

A subgroup analysis based on the HR was conducted. The analysis of pCR outcomes stratified by HR status revealed that the HR status contributes to the difference in 

The subgroup analysis of the four single-arm trials showed that the efficacy of H + P in HR- (pCR rate range, 0.69–0.85; absolute rate = 0.77; 95% CI, 0.67–0.87; P < 0.001) was more significant than that in HR+ (pCR rate range, 0.26–0.68; absolute rate = 0.46; 95% CI, 0.21–0.70; P < 0.001). Significant het-

Four controlled trials including 1448 patients (n = 383 in the experimental H + P groups and n = 1065 in the control H groups) were analyzed for the pCR rate in stage -III HER2+ breast cancer patients [22–25]. The pooled results using a fixed-effects model demonstrated that the pCR rate of the H + P group was significantly higher than that of the H group (OR = 1.33; 95% CI, 1.08–1.63; P = 0.006) (Fig. 2b). Low heterogeneity was found among the included individual studies (I² = 0.0%; P = 0.78), and no publication bias was not detected using Begg’s test (P = 0.734) and Egger’s test (P = 0.80). Moreover, the absolute pCR rates of the H + P and H groups were estimated to equal 55 and 44%, respectively.

A subgroup analysis based on the HR was conducted. The analysis of pCR outcomes stratified by HR status revealed that the HR status contributes to the difference in 
efficacy between H + P and H. A subgroup analysis of the four single-arm trials showed that the efficacy of H + P in HR- (pCR rate range, 0.69–0.85; absolute rate = 0.77; 95% CI, 0.67–0.87; P < 0.001) was more significant than that in HR+ (pCR rate range, 0.26–0.68; absolute rate = 0.46; 95% CI, 0.21–0.70; P < 0.001). Significant het-
erogeneity was observed in the HR+ group (I² = 86.4%; 
P = 0.001) (Fig. 2a). The sensitivity analysis yielded an es-
timated absolute rate of 0.35 (95% CI, 0.21–0.70) after sequential exclusion of the study conducted by Jasmeet C. Singh. The subgroup analysis based on HR was per-
formed in three studies, the results of the benefit ratio 
showed that there was a trend towards better pCR of 
HR+ patients compared to that of HR- patients [absolute rate (HR-)= 0.68; absolute rate (HR+)= 0.39]. However, the results of comparison between group H + P and group H on the efficacy of H + P 
and group H on the efficacy of H + P was not significantly better than that of H in HR+ (absolute rate = 0.39 versus 0.30) or HR- (absolute rate = 0.68 versus 0.51) breast cancer patients, and the pooled estimates using a fixed-effects model indicated no sig-
ificant difference between HR+ (OR = 1.37; 95% CI, 0.88–2.13; P = 0.162) and HR- (OR = 1.37; 95% CI, 0.91– 2.07; P = 0.126) breast cancer patients (Fig. 2b).
PFS and OS in metastatic studies or settings
Thirteen trials reported the median PFS [9, 14, 18–21, 26–30, 32, 33], and four of these trials also reported OS [9, 18, 19, 21]. The robust pooled results using a fixed-effects model demonstrated that H + P might stabilize diseases and prolong the survival of HER2+ MBC. The hazard ratio was 0.75 (95% CI, 0.68–0.84; P < 0.001) (Fig. 3), which indicated that H + P significantly improved the median PFS in patients with HER2+ MBC. Low statistical heterogeneity among the included studies was noted (I^2 = 32.8%; P = 0.203) in the PFS analysis (Fig. 3). We found no evidence of publication bias in any of the analyses using Begg’s test (P = 1.00) and Egger’s test (P = 0.974).

Regarding OS, there was a trend towards better OS but that it did not reach statistical significance (HRs =

| Study                         | Random sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Bias from other resources |
|-------------------------------|-----------------------------|------------------------|----------------------------------------|-------------------------------|------------------------|----------------------|---------------------------|
| Shruti R. Tiwari 2016 [25]    | Low risk                    | Unclear                | Unclear                                | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Sandra M.Swain 2015 [19]      | Low risk                    | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Sabino De Placido 2018 [33]   | Low risk                    | High risk              | Unclear                                | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Rashmi K. Murthy 2018 [17]    | Low risk                    | Unclear                | Unclear                                | Low risk                      | High risk              | Low risk             | Low risk                  |
| Peter Beitsch 2017 [10]       | Low risk                    | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Nicholas J. Robert 2017 [32]  | Low risk                    | Unclear                | Unclear                                | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Nadia Hussain 2018 [35]       | Unclear                     | Unclear                | Unclear                                | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Mothaffar Rimawi 2017 [18]    | Low risk                    | Unclear                | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Andersson M 2017 [26]         | Low risk                    | Unclear                | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Manish Gupta 2013 [11]        | Low risk                    | Low risk               | Low risk                               | Low risk                      | High risk              | High risk            | Unclear                   |
| M. Martin 2016 [13]           | High risk                   | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Luca Gianni 2018 [22]         | Low risk                    | Unclear                | Low risk                               | Low risk                      | Low risk               | Low risk             | High risk                 |
| Luca Gianni 2012 [15]         | Low risk                    | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Kazuhiro Araki 2017 [14]      | Low risk                    | Low risk               | Unclear                                | Low risk                      | Unclear                | Low risk             | High risk                 |
| Kathy D. Miller 2014 [34]     | Low risk                    | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Julia Foldi 2017 [23]         | Low risk                    | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| José Baselga 2010 [36]        | Low risk                    | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| JASMEET C. SINGH 2017 [24]    | Unclear                     | Unclear                | Unclear                                | Low risk                      | Low risk               | Low risk             | Unclear                   |
| Ian Ehsop 2016 [20]           | Low risk                    | Unclear                | Low risk                               | Low risk                      | Low risk               | High risk            | Low risk                  |
| Gunter von Minckwitz 2017 [16]| Low risk                    | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Edith A. Perez 2017 [21]      | Low risk                    | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Edith A. Perez 2016 [27]      | Low risk                    | Unclear                | Unclear                                | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Chia C. Portera 2008 [31]     | Low risk                    | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Chau Dang 2015 [28]           | Low risk                    | Unclear                | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Bao D Dao 2015 [29]           | Unclear                     | Unclear                | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
| Ander Urruticoechea 2017 [9]  | Low risk                    | Low risk               | Low risk                               | Low risk                      | Low risk               | Low risk             | Low risk                  |
Study or Subgroup

**A** pCR

| HR+                | Proportion (95% CI) | Weight % |
|-------------------|---------------------|----------|
| Julia Foldi (2017)| 0.26 (0.08, 0.44)   | 31.93    |
| JASMEET C. SINGH (2017) | 0.68 (0.54, 0.82)   | 34.41    |
| Shruti R. Tiwari (2016) | 0.41 (0.26, 0.57)   | 33.66    |
| Subtotal (I−squared = 86.4%, p = 0.001) | 0.46 (0.21, 0.70)   | 100.00   |

**HR−**

| HR−                | Proportion (95% CI) | Weight % |
|-------------------|---------------------|----------|
| Julia Foldi (2017)| 0.80 (0.64, 0.96)   | 39.90    |
| JASMEET C. SINGH (2017) | 0.85 (0.65, 1.04)   | 25.50    |
| Shruti R. Tiwari (2016) | 0.69 (0.52, 0.86)   | 34.60    |
| Subtotal (I−squared = 0.0%, p = 0.452) | 0.77 (0.67, 0.87)   | 100.00   |

**HR−Mix**

| Luca Gianni (2018) | 0.27 (0.11, 0.42)   | 22.77    |
|-------------------|---------------------|----------|
| Julia Foldi (2017)| 0.54 (0.40, 0.68)   | 24.31    |
| JASMEET C. SINGH (2017) | 0.62 (0.50, 0.74)   | 26.45    |
| Shruti R. Tiwari (2016) | 0.53 (0.41, 0.65)   | 26.46    |
| Subtotal (I−squared = 76.6%, p = 0.005) | 0.50 (0.36, 0.63)   | 100.00   |
| Overall (I−squared = 82.4%, p = 0.000) | 0.56 (0.45, 0.68)   |          |

**Study or Subgroup

**B** pCR

| HR+                | OR (95% CI) | Weight % |
|-------------------|-------------|----------|
| Peter Beitsch (2017) | 1.61 (0.92, 2.82) | 62.19    |
| Luca Gianni (2012)   | 1.30 (0.52, 3.24) | 23.39    |
| M. Martin (2016)     | 0.74 (0.23, 2.36) | 14.42    |
| Subtotal (I−squared = 0.0%, p = 0.491) | 1.37 (0.88, 2.13) | 100.00   |

**HR−**

| HR−                | OR (95% CI) | Weight % |
|-------------------|-------------|----------|
| Peter Beitsch (2017) | 1.23 (0.68, 2.24) | 46.74    |
| Luca Gianni (2012)   | 1.71 (0.89, 3.29) | 39.17    |
| M. Martin (2016)     | 1.07 (0.36, 3.17) | 14.09    |
| Subtotal (I−squared = 0.0%, p = 0.679) | 1.37 (0.91, 2.07) | 100.00   |

**HR−MIX**

| Peter Beitsch (2017) | 1.41 (0.94, 2.12) | 25.46    |
| Luca Gianni (2017)   | 1.58 (0.94, 2.67) | 15.20    |
| Rashmi K. Murthy (2012) | 1.28 (0.96, 1.70) | 51.96    |
| M. Martin (2016)     | 1.01 (0.48, 2.14) | 7.38     |
| Subtotal (I−squared = 0.0%, p = 0.778) | 1.33 (1.08, 1.63) | 100.00   |
| Overall (I−squared = 0.0%, p = 0.950) | 1.34 (1.14, 1.59) |          |

---

Fig. 2 (See legend on next page.)
0.81; 95% CI, 0.64–1.03; p = 0.082) (Fig. 3). No significant heterogeneity was observed (I2 = 59.8%; P = 0.058) (Fig. 3). The sensitivity analysis revealed an estimated HR of 0.71 (95% CI, 0.61–0.84) after removing the study conducted by Edith A. Perez. We also found no evidence of publication bias in any of the analyses using Begg’s test (P = 0.308) and Egger’s test (P = 0.216).

Secondary outcomes

Relative risk of adverse reactions

We recorded and evaluated the AEs in all 26 trials, and the most common all-grade AEs were rash, diarrhea, myalgia, epistaxis, and mucosal inflammation. We calculated the overall rate and 95% CI for some adverse reactions in the single-arm trials using a random effects model (Fig. 4). The rates ranged from 6 to 80% for rash, 34 to 92% for diarrhea, and 9 to 37% for epistaxis. The pooled absolute rates for rash, diarrhea, and epistaxis were 0.32 (95% CI, 0.19–0.46), 0.59 (95% CI, 0.47–0.71), and 0.19 (95% CI, 0.11–0.28), respectively. The sensitivity analysis showed that the pooled absolute rates for rash, diarrhea, and epistaxis were 0.8 (95% CI, 0.5–0.11), 0.41 (95% CI, 0.37–0.45), and 0.15 (95% CI, 0.11–0.18) after removing the studies conducted by José Baselga, Julia Foldi, Kazuhiro Araki, Edith A. Perez, Chau Dang, and Nicholas J. Robert. The analysis using a fixed-effects model of AEs in the controlled trials showed that the H + P group was associated with a significantly higher incidence of all-grade rash (OR = 1.36; 95% CI, 1.22–1.51; P < 0.001), diarrhea (OR = 1.36; 95% CI, 1.17–1.56; P < 0.001), epistaxis (OR = 1.26; 95% CI, 1.11–1.43; P < 0.001), and mucosal inflammation (OR = 1.25; 95% CI, 1.11–1.41; P < 0.001) compared with the H group. Interestingly, a tendency toward a significantly reduced incidence of myalgia was found in the H + P group (OR = 0.91; 95% CI, 0.81–1.01; P = 0.065). The analysis of most common all-grade AEs of H + P indicated that pertuzumab played a prominent role in the incidences of rash, diarrhea, epistaxis, myalgia, and mucosal inflammation (Fig. 5).

Among AEs of grade ≥ 3, three common AEs were neutropenia, diarrhea, and anemia. The rates for diarrhea ranged from 0.016 to 0.14, and the pooled absolute rate for diarrhea was 0.5 (95% CI, 0.4–0.7). In the controlled trials, the rates of diarrhea and anemia in the experimental group were significantly higher than those in the controlled group [(OR = 2.42; 95% CI, 1.94–3.02; P = 0.0001) and (OR = 1.43, 95% CI, 1.14–1.79, P = 0.002), respectively]. A significant difference was not observed in neutropenia (OR = 0.99, 95% CI, 0.86–1.13, P = 0.814) (Fig. 5).

Cardiac toxicity

The data for an LVEF decline <50% or more than 10% from baseline obtained in 15 trials were analyzed. In all the studies, the LVEF was assessed at baseline and then every 3 months. The percentage of patients who experienced cardiac toxicity ranged from 0.002 to 0.27, and the pooled absolute rate for cardiac toxicity was 0.02 (95% CI, 0.01–0.03) (Fig. 4). In the controlled trials, cardiac toxicity was analyzed using a fixed-effects model, and the results showed that H + P did not increase the incidence of LVEF compared with the effect of H (OR = 1.26; 95% CI, 0.81–1.95; P = 0.309) (Fig. 5).

Discussion

In this meta-analysis, we evaluated the efficacy and safety of H + P versus H for the treatment of patients with HER2+ breast cancer in (neo)adjuvant settings. The development of the first HER2-targeted therapy, trastuzumab, transformed (and significantly improved) the traditional remedies and induced AEs in the treatment of HER2+ breast cancer patients, which led to its initial approval in 1998. Despite these advances, the resistance to and severe toxicity of trastuzumab forced the development of additional anti-HER2 targeted therapies and the continuous exploration of combinatorial-targeted strategies. The development of new targeted agents, such as pertuzumab and T-DM1, revolutionized the therapeutic strategy of HER2+ breast cancer patients in clinical settings. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of patients with HER2+ breast cancer has been approved by the Food and Drug Administration. T-DM1, a complex agent that combines the mechanisms of trastuzumab and maytansine, minimizes toxicity by selectively delivering the cytotoxic agent to tumor cells, thereby minimizing systemic exposure. The research prospects of the combination of pertuzumab with T-DM1 are well worth exploring. Randomized controlled trials investigating the combination of pertuzumab and T-DM1 for the treatment of breast cancer have been published in recent years [11, 13, 20, 21]. Pertuzumab-based dual anti-HER2 therapies have been widely used in the clinic, and thus, many retrospective trials are included in our study. To our
knowledge, this systematic review and meta-analysis constitutes the first investigation of the benefit of H + P (pertuzumab plus trastuzumab or trastuzumab emtansine) versus H (trastuzumab or trastuzumab emtansine) and involves the first subgroup analysis conducted with respect to HR.

We observed that HER2+ breast cancer patients with a mixed HR status (positive or negative) benefited from H + P therapy in terms of pCR, PFS, and OS, regardless of the choice of chemotherapy.

In the neoadjuvant phase, the analysis of pCR (absolute difference = 11.0%; OR = 1.33; 95% CI, 1.08–1.63;
Fig. 4 Forest plots of common adverse events and cardiotoxicity events in single-arm studies: combination of pertuzumab with HER2 inhibitors for patients with HER2+ breast cancer. HER2 = human epidermal growth factor receptor 2
HER2+ breast cancer patients receiving pertuzumab achieved a greater benefit from H + P compared with that achieved from H. Peter Beitsch et al. reported a higher pCR rate than that obtained in other studies [10], and his study outcome showed that the pCR in the H + P group was higher than that in the H group (57.0 and 40.0%, respectively), with an absolute difference of 17.0%. A network meta-analysis conducted by Aiko Nagayama et al. that compared H + P with H also showed a significant difference in the pCR (OR = 2.29; 95% CI, 1.02–5.02; \(P = 0.02\)) [36]. A randomized controlled trial (NeoSphere) evaluated the efficacy of three treatment groups (group H + P, group H, and group P) [15]. This study showed that patients given H + P had a significantly improved pCR compared with those given H (45.8 and 29.0%, respectively), patients given P received the lowest pCR (24.0%). Currently, due to the lack of research on pertuzumab monotherapy, the only clinical trial (NeoSphere) involving pertuzumab monotherapy was analyzed in our research.

In metastatic settings, the H + P treatment of patients with HER2+ demonstrated significant benefits on PFS (HRs = 0.75; 95% CI, 0.68–0.84; \(P < 0.00001\)) (Fig. 3). This result indicated that H + P has a clear tendency to prolong survival. Unfortunately, statistical significance was not observed in the OS analysis (HRs = 0.81; 95% CI, 0.64–1.03; \(P = 0.082\)) (Fig. 3). However, we found that the efficacy of group H + P was superior to that of group H by analyzing the OS/PFS results and trended towards better OS which did not reach statistical significance. Further larger scale, well-designed RCTs are needed to identify this trend. The similar results presented in the CLEOPATRA study, a phase III study that included 808 patients with HER2+ MBC, were randomized to pertuzumab + trastuzumab + docetaxel or trastuzumab + docetaxel + placebo. In this study, the comparison of H + P and H revealed that survival was prolonged by 6.3 months. The difference in PFS was significant (HRs = 0.69, 95% CI, 0.58–0.81; \(P < 0.001\)), and a significant benefit in OS was observed in the patients allocated to the combined treatment group compared with those assigned to the control group (HRs = 0.66; 95% CI, 0.52–0.84; \(P < 0.001\)) [9].

Our subgroup analysis showed that H + P and H exerted different impacts on pCR outcomes according to the HR status in the neoadjuvant phase. This analysis demonstrated that the benefit from H + P was more evident in HR- than in HR+, with distinct increases of 78.0

\(P = 0.006\) (Fig. 2a and b) showed that HER2+ breast cancer patients receiving pertuzumab achieved a greater benefit from H + P compared with that achieved from H.
and 45.0% in the absolute rate of pCR in the single-arm trials (P < 0.001), respectively (Fig. 2a). In contrast, a significant difference was not observed in patients with HER2+/HR+ breast cancer (OR = 1.37; 95% CI, 0.88–2.13; P = 0.165) or HER2+/HR- breast cancer (OR = 1.37; 95% CI, 0.91–2.07; P = 0.123) in controlled trials (Fig. 2b). Although similar outcomes were obtained from the comparison between the HR+ group and the HR- group, the clinical advantage from H + P is more significant in HR- than in HR+, with absolute increases of 17.0 and 9.0%, respectively. Our result was consistent with those obtained in other studies investigating the effects of combined therapy on HER2+ tumors. Gianni L et al. reported that H + P yielded higher PCR rates in HR-/HER2+ breast cancer compared with those achieved in HR+/HER2+ breast cancer (63.2 and 26.0%, respectively) [15], and M. Martin et al. reported a 36.5% improvement in the outcomes of pCR after H + P therapy in the comparison of HR-/HER2+ and HR+/HER2+ breast cancer patients. Thus, we suggest that H + P could be considered a beneficial therapeutic opportunity for patients with HER2+ breast cancer and a negative HR status. The biological mechanisms underlying the different effects according to HR status are unclear, but HR expression has been associated with anti-HER2 drug resistance in preclinical and clinical models, possibly due to cross-talk inhibition between growth-promoting pathways [37, 38].

Regarding the safety profile, the incidence of all-grade AEs, including rash, diarrhea, epistaxis, and mucosal inflammation, was significantly higher among HER2+ patients treated with H + P than among those treated with H. Interestingly, a downward trend in the incidence of myalgia was observed (OR = 0.91; 95% CI, 0.82–1.01; P = 0.072) (Fig. 5). Among AEs of grade ≥ 3, only diarrhea and anemia were significantly more frequent in the H + P group than in the H group, and the incidence of other AEs was not significantly aggravated (Fig. 5). In the PHEREXA trial, the highest risk of severe diarrhea was observed in the H + P group compared with that in the H group (16.2% versus 10.1%), with a significant difference of 6.1%. In the Neosphere trial, regardless of the all-grade AEs (rash, diarrhea, and mucosal inflammation) or AEs of grade ≥ 3 (diarrhea), the risk of H + P group was higher than that of H group and P group, and the risk of P group was the lowest among the three groups. Gastrointestinal toxicity showed a strong relationship with pertuzumab treatment. Previous studies have shown that the proper functioning of the gastrointestinal tract relies on the expression of HER2 receptors in many vital structures [39], such as epithelial cells and enteric nervous system neurons [40]. Pertuzumab might act on the receptors of these normal cells and interfere with their functions, leading to gastrointestinal toxicity. Rash was the most common side effect of targeted therapies. The occurrence of rash appears to be related to the mechanism through which pertuzumab acts on the HER2 receptors of cells, similar to the mechanism associated with the occurrence of diarrhea. EGFR is the major HER/ErbB receptor expressed on human keratinocytes [41], and HER2 heterodimerizes with EGFR and ErbB3 [42]. Hence, some functional EGFR–HER2 interactions likely occur in skin, and these are likely amendable to blockade by pertuzumab. Nonetheless, future studies are needed to more clearly elucidate the mechanism of pertuzumab. Many times, these typically toxicities of therapies in clinical practice are higher than those in clinical trials due to careful selection of patients with good performance status, good organ function and excellent health otherwise. We also confirmed this statement by consulting clinicians. We found that these adverse reactions are quite common for targeted therapies, and the safety profiles of particular targeted agents are well known by breast cancer patients, which helps to reduce or even prevent the risk of some AEs. However, we must attach importance to the risk of toxicity of anti-HER2 dual block therapies to maximize patient benefit. In the clinic, doctors may adjust the dose according to the individual needs of the patients with the aim of reducing the occurrence of AEs or take measures to prevent these effects.

Our study also analyzed heart safety profiles because the HER2 signaling pathway plays an important role in cardiac physiology [43]. The outcomes observed in 17 single-arm trials showed that HER2-targeted therapies including pertuzumab are harmful to heart safety (Fig. 4). However, our analysis of controlled trials revealed no increased risk of cardiac toxicity associated with the addition of pertuzumab to anti-HER2 therapies (Fig. 5), which is consistent with the results of a previous study conducted by Antonis Valachis et al. [44].

The addition of pertuzumab to HER2-targeted monotherapy reduced the risk of disease recurrence and death among patients who had developed drug resistance due to long-term treatment with single HER2 inhibitors, and the incidence of serious adverse reactions caused by the use of high-dose single HER2 inhibitors was decreased. The comparison of the benefits between the two treatment groups revealed that the H + P groups still showed a strong advantage, regardless of whether they were combined with chemotherapy (palbociclib, fulvestrant, vinorelbine, taxane, eribulin, doxorubicin+cyclophosphamide, carboplatin, paclitaxel, fluorouracil+epirubicin+cyclophosphamide, and aromatase inhibitors). Additionally, we summarized the administered dosages of H + P included in this study. Among the included trials, the most common administrations were pertuzumab or placebo (a loading dose of 840 mg administered intravenously
followed by a dose of 420 mg administered intravenously every 3 weeks) and trastuzumab (a loading dose of 8 mg/kg administered intravenously followed by a dose of 6 mg/kg administered intravenously every 3 weeks) or T-DM1 (3.6 mg/kg). Our results not only enhance the prominent role of pertuzumab added to dual anti-HER2 targeted therapies in the (neo)adjuvant treatment of HER2+ breast cancer but also alleviated some of the confusion regarding the benefit of adding pertuzumab to HER2 therapies and effectively revealed the importance of individualized therapy.

This review has several strengths and limitations. First, to our knowledge, this study constitutes the systematic review and meta-analysis aiming to investigate the benefit of anti-HER2 dual blockade (pertuzumab plus trastuzumab or trastuzumab emtansine) compared with that of monotherapy (trastuzumab or trastuzumab emtansine) and includes the first subgroup analyses conducted with respect to the HR status. Second, our study included a sufficiently large sample, which increases the statistical power of the evaluation of the effect of the combination treatment. Third, we also assessed the effects of dual-blockage treatment on a subgroup of patients with different HR statuses. Fourth, we evaluated the efficacy and safety of the treatment of patients with HER2+ breast cancer at various stages. Several limitations include the following. First, several of the controlled trials lacked complete data and included nonrandomized controlled trials, and fewer samples were included in the single-arm trials. Second, the calculations were based on published study results and presented clinical trials rather than individual patient data, which might generate biases.

**Conclusions**

In conclusion, the results of this systematic review and meta-analysis provide the first opportunity to compare the efficacy and safety of HER2 inhibitors with (H + P) or without pertuzumab (H) for patients with HER2+ breast cancer. Our meta-analysis confirms that H + P is superior to H in the (neo)adjuvant treatment of HER2+ breast cancer, and increase the risk of acceptable and tolerable toxicity (rash, diarrhea, epistaxis, mucosal inflammation, and anemia). Based on the subgroup analysis of pCR, H + P is a correct choice for the treatment of patients with HER2+/HR- breast cancer. The combined application of pertuzumab and HER2-targeted drugs is thus promising and potent.

**Abbreviations**

AEs: Adverse events; CI: Confidence interval; H + P: HER2 inhibitors + pertuzumab ± chemotherapy; H: HER2 inhibitors ± chemotherapy; HER2: Human epidermal growth factor receptor 2; HR: Hormone receptor negative; HR+: Hormone receptor positive; HRs: Hazard ratios; LVEF: Left ventricular ejection fraction; OR: Odds ratio; OS: Overall survival; pCR: Pathologic complete response; PFS: Progression-free survival; RCT: Randomized controlled trial; T-DM1: Trastuzumab emtansine

**Acknowledgements**

The authors would like to thank Mr. Hao Shi for providing guidance on clinical applications, Miss. Xuewei Zhao for her advice and assistance with the data processing and all the patients who participated in this study.

**Authors’ contributions**

SSC and MXW conceived of the idea, designed the study, defined the search strategy and selection criteria, and were the major contributors in writing the manuscript. ZYF and YL performed the literature search and the analyses. All the authors contributed to the writing and editing of the manuscript. All authors read and approved the final manuscript, and ensured that this is the case.

**Funding**

There was no funding for this study.

**Availability of data and materials**

All data are available in this manuscript.

**Ethics approval and consent to participate**

This research work constitutes a meta-analysis of published data and does not include any studies with human participants or animals performed by any of the authors. Hence, no informed consent was required to perform this study.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

Received: 21 May 2019 Accepted: 3 September 2019

Published online: 21 October 2019

**References**

1. Giordano SH, Tsimakos P, Korter JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. Clin Oncol. 2014;32:2078–99.

2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

3. Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anti-Cancer Drugs. 2012;23:765–76.

4. Oostra DR, Macrae ER. Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer. Breast Cancer. 2014;6:103–13.

5. Baselga J, Svien AM. Novel anticancer targets: revisiting ErbB2 and discovering ErbB3. Nat Rev Cancer. 2009;9:463–75.

6. Scheuer W, Fries T, Burgacher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. CancerRes. 2009;69:9330–6.

7. Metzger-Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin Cancer Res. 2013;19:5552–6.

8. Cai Z, Zhang G, Zhou Z, et al. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3/p185HER2/neu and the EGF-p185HER2/neu complexes. Oncogene. 2008;27:3870–4. https://doi.org/10.1038/onc.2008.13.

9. Unnurson Cochee A, Rizwanullah M, Im SA, Muñoz M, et al. Randomized phase II trial of Trastuzumab plus Cetuximab with or without Pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast Cancer who experienced disease progression during or after Trastuzumab-based therapy. J Clin Oncol. 2017;35(28):3030–8.

10. Bentsch P, Wuthworth P, Baron P, et al. Pertuzumab/Trastuzumab/CT versus Trastuzumab/CT therapy for HER2+ breast Cancer: results from the prospective neoadjuvant breast registry symphony trial (NBRST). Ann Surg Oncol. 2017;24(9):2539–46.

11. Gupta M, Wang B, Canrothers TJ, Gersh S, et al. Effects of Trastuzumab Emtansine (T-DM1) on QT interval and safety of Pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast Cancer. Clin Pharmacol Drug Dev. 2013;2(1):11–24.

12. Higgins JPT, Altman DG, Götzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
13. Martin M, Fumoleau P, Dewar JA, Garcia-Saenz JA, et al. Trastuzumab emtansine (T-DM1) plus doxetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Ann Oncol. 2016;27(1):1249–56.

14. Araki K, Fukuda J, Yanagi H, Ito Y, et al. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer. Breast. 2017;35:78–84.

15. Gianni L, Penkovski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1): 51–57.

16. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(7):702.

17. Murthy RK, Raghavendra AS, Hess KK, Ueno NT, et al. Neoadjuvant Pertuzumab-containing regimens improve pathologic complete response rates in stage II to III HER2-negative breast cancer: a retrospective, single institution experience. Clin Breast Cancer. 2018;18(6):e128–8.

18. Rimawi M, Ferro J-M, de la Haba-Rodriguez J, et al. First-line Trastuzumab plus an aromatase inhibitors, with or without Pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36(28):2826–35.

19. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:274–9.

20. Krop IE, Modi S, LoRusso PM, Elias A, et al. Phase IIa trial of trastuzumab Emtansine with Pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol. 2014;32(14):1437–44.

21. Hussain N, Said ASA, Khan Z. Safety assessment of neoadjuvant Pertuzumab combined with Trastuzumab in nonmetastatic HER2-positive breast cancer in postmenopausal elderly women of South Asia. Int J Breast Cancer. 2018;2018:106041.

22. Gianni L, Bisagni G, Colleoni M, Viale G, et al. Neoadjuvant treatment with weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer. Breast Cancer Res Treat. 2016;158(1):189–97.

23. Foldi J, Mougalian S, Silber A, Pusztai L, et al. Single-arm, neoadjuvant, Trastuzumab and Pertuzumab from the phase III MARINAne study. J Clin Oncol. 2017;35(2):141–8.

24. Singh JC, Mamanti A, Bario A, Dang C, et al. Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with Trastuzumab and Pertuzumab in patients with HER2-positive early stage breast Cancer: a single center experience. Oncologist. 2017;22(10):1160.

25. Tiwari SR, Mishra P, Raska P, Montero AJ, et al. Retrospective study of the efficacy and safety of neoadjuvant doxetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Breast Cancer Res Treat. 2016;158(1):189–93.

26. Andersson M, López-Vega JM, Pettit T, Perez EA, et al. Efficacy and safety of Pertuzumab and Trastuzumab administered in a single infusion bag, followed by Vinorelbine: VELVET cohort 2 final results. Oncologist. 2017;22(10):1160–8.

27. Perez EA, Lopez-Vega JM, Pettit T, Andersson M, et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET cohort 1 final results. Breast Cancer Res. 2016;18(1):126.

28. Dang C, Iyengar N, Datko F, Hudis C, et al. Phase II study of paclitaxel given once per week along with Trastuzumab and Pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior Trastuzumab therapy. J Clin Oncol. 2010;28(7):1138–44.

29. Portera CC, Walshe JM, Rosing DR, Swain SM, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive HER2-positive metastatic breast cancer. Clin Cancer Res. 2008;14(9):2710–6.

30. Robert NJ, Goetz HP, Chopra P, Antao V, et al. HER2-positive metastatic breast Cancer patients receiving Pertuzumab in a community oncology practice setting:treatment patterns and outcomes. Drugs Real World Outcomes. 2017;4(1):1–7.

31. De Placido S, Giuliano M, Schettini F, Arpino G, et al. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast. 2018;38:86–91.

32. Miller KD, Dielers V, Harbeck N, Burris HA, et al. Phase IIa trial of Trastuzumab Emtansine with Pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol. 2014;32(14):1437–44.